BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
Bergen, Norway, 1 February 2023 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the fourth quarter 2022 on Thursday 16 February 2023. The briefing will take place at 10:00 am CET at:
Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo
where BerGenBio's senior management team will provide an update on the Company followed by a Q&A session. To attend in person please register by mail to ir@bergenbio.com
The presentation will webcast live and a link will be available at www.bergenbio.com in the Investors/Financial Reports section and a recording will be available shortly after the webcast has finished.
The fourth quarter financial report and presentation will be made available on the Company’s website in the Investors/Financial Reports section from 7:00am CET the same day.
-End-
Contacts
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Investor Relations / Media Relations
Graham Morrell
+1 781 686 9600
Media Relation Norway
Jan Lilleby
+47 90 55 16 98
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.